Related references
Note: Only part of the references are listed.Ivermectin 21st Century Snake Oil or Safe and Effective for COVID-19?
Patricia Anne O'Malley
CLINICAL NURSE SPECIALIST (2022)
The mechanisms of action of Ivermectin against SARS-CoV-2: An evidence-based clinical review article
Asiya Kamber Zaidi et al.
JOURNAL OF ANTIBIOTICS (2022)
Silent COVID-19: what your skin can reveal
Claudio Guarneri et al.
LANCET INFECTIOUS DISEASES (2021)
Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019 The Ivermectin in COVID Nineteen Study
Juliana Cepelowicz Rajter et al.
CHEST (2021)
Headache during SARS-CoV-2 infection as an early symptom associated with a more benign course of disease: a case-control study
Alicia Gonzalez-Martinez et al.
EUROPEAN JOURNAL OF NEUROLOGY (2021)
A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ivermectin
Martin D. Hellwig et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2021)
Chloroquine and hydroxychloroquine in the treatment of COVID-19: the never-ending story
Amin Gasmi et al.
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY (2021)
Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19 A Randomized Clinical Trial
Eduardo Lopez-Medina et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19
Pierre Kory et al.
AMERICAN JOURNAL OF THERAPEUTICS (2021)
Potential use of ivermectin for the treatment and prophylaxis of SARS-CoV-2 infection
R. Cobos-Campos et al.
CURRENT RESEARCH IN TRANSLATIONAL MEDICINE (2021)
A Comparative Study on Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin Therapy on COVID-19 Patients
Abu Taiub Mohammed Mohiuddin Chowdhury et al.
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY (2021)
The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial
Carlos Chaccour et al.
ECLINICALMEDICINE (2021)
Note from the editors: World Health Organization declares novel coronavirus (2019-nCoV) sixth public health emergency of international concern
EUROSURVEILLANCE (2020)
Safety of high-dose ivermectin: a systematic review and meta-analysis
Miriam Navarro et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Ivermectin and COVID-19: Keeping Rigor in Times of Urgency
Carlos Chaccour et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2020)
The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19
Virginia D. Schmith et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Objective evaluation of anosmia and ageusia in COVID-19 patients: Single-center experience on 72 cases
Luigi Angelo Vaira et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2020)
Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof)
Prakhar Vijayvargiya et al.
MAYO CLINIC PROCEEDINGS (2020)
Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19)
Katelyn A. Pastick et al.
OPEN FORUM INFECTIOUS DISEASES (2020)
Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action
Emanuele Rizzo
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2020)
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
Leon Caly et al.
ANTIVIRAL RESEARCH (2020)
COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2)
Yang Song et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen
Fatemeh Heidary et al.
JOURNAL OF ANTIBIOTICS (2020)
Attenuated Interferon and Proinflammatory Response in SARS-CoV-2-Infected Human Dendritic Cells Is Associated With Viral Antagonism of STAT1 Phosphorylation
Dong Yang et al.
JOURNAL OF INFECTIOUS DISEASES (2020)
An aberrant STAT pathway is central to COVID-19
Toshifumi Matsuyama et al.
CELL DEATH AND DIFFERENTIATION (2020)
Advances in the possible treatment of COVID-19: A review
Pankaj Chibber et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2020)
SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant
Yoriyuki Konno et al.
CELL REPORTS (2020)
Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal?
David A. Jans et al.
CELLS (2020)
Therapeutic potential of ivermectin as add on treatment in COVID 19: A systematic review and meta-analysis
Biswa Mohan Padhy et al.
JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES (2020)
Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients
Daniel Camprubi et al.
PLOS ONE (2020)
A Case of Vasculitis-Like Skin Eruption Associated With COVID-19
Nicholas Geremia et al.
INFECTIOUS DISEASES IN CLINICAL PRACTICE (2020)
Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens
Georgi Momekov et al.
BIOTECHNOLOGY & BIOTECHNOLOGICAL EQUIPMENT (2020)
Ivermectin Docks to the SARS-CoV-2 Spike Receptor-binding Domain Attached to ACE2
Steven Lehrer et al.
IN VIVO (2020)
Clinical Presentation, Management and In-Hospital Outcome of Healthcare Personnel With COVID-19 Disease
Fazila-Tun-Nesa Malik et al.
CUREUS JOURNAL OF MEDICAL SCIENCE (2020)
Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance
R. Choudhary et al.
NEW MICROBES AND NEW INFECTIONS (2020)
Antiviral Activity of Ivermectin Against SARS-CoV-2: An Old-Fashioned Dog with a New Trick-A Literature Review
Mudatsir Mudatsir et al.
SCIENTIA PHARMACEUTICA (2020)
Antiviral treatment of COVID-19
Serap Simsek Yavuz et al.
TURKISH JOURNAL OF MEDICAL SCIENCES (2020)
Serious Neurological Adverse Events after Ivermectin-Do They Occur beyond the Indication of Onchocerciasis?
Rebecca E. Chandler
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2018)
Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial
Menno R. Smit et al.
LANCET INFECTIOUS DISEASES (2018)
Safety and pharmacokinetic profile of fixed-dose ivermectin with an innovative 18mg tablet in healthy adult volunteers
Jose Munoz et al.
PLOS NEGLECTED TROPICAL DISEASES (2018)
Incidence and admission rates for severe malaria and their impact on mortality in Africa
Flavia Camponovo et al.
MALARIA JOURNAL (2017)
Ivermectin - Old Drug, New Tricks?
Roz Laing et al.
TRENDS IN PARASITOLOGY (2017)
Drug-transporter mediated interactions between anthelminthic and antiretroviral drugs across the Caco-2 cell monolayers
Gabriel Kigen et al.
BMC PHARMACOLOGY & TOXICOLOGY (2017)
The blood-brain barrier in systemic inflammation
Aravinthan Varatharaj et al.
BRAIN BEHAVIOR AND IMMUNITY (2017)
Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection
Cesar Henriquez-Camacho et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2016)
Persistent Coma in Strongyloides Hyperinfection Syndrome Associated With Persistently Increased Ivermectin Levels
David J. van Westerloo et al.
CLINICAL INFECTIOUS DISEASES (2014)
Ivermectin: panacea for resource-poor communities?
Satoshi Omura et al.
TRENDS IN PARASITOLOGY (2014)
Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus
Kylie M. Wagstaff et al.
BIOCHEMICAL JOURNAL (2012)
The pharmacokinetics and metabolism of ivermectin in domestic animal species
Aranzazu Gonzalez Canga et al.
VETERINARY JOURNAL (2009)
The pharmacokinetics and interactions of ivermectin in humans - A mini-review
Aranzazu Gonzalez Canga et al.
AAPS JOURNAL (2008)
Ivermectin: pharmacology and application in dermatology
AL Dourmishev et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2005)
Influence of the route of administration on efficacy and tissue distribution of ivermectin in goat
A Lespine et al.
VETERINARY PARASITOLOGY (2005)
Adverse systemic reactions to treatment of onchocerciasis with ivermectin at normal and high doses given annually or three-monthly
J Kamgno et al.
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE (2004)
The life and times of ivermectin - a success story
S Omura et al.
NATURE REVIEWS MICROBIOLOGY (2004)
Unmasking the dynamic interplay between efflux transporters and metabolic enzymes
LZ Benet et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2004)
Variation in incidence of serious adverse events after onchocerciasis treatment with ivermectin in areas of Cameroon co-endemic for loiasis
NAY Twum-Danso et al.
TROPICAL MEDICINE & INTERNATIONAL HEALTH (2003)
Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects
CA Guzzo et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Effect of ivermectin on activities of cytochrome P450 isoenzymes in mouflon (Ovis musimon) and fallow deer (Dama dama)
L Skálová et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2001)
Share Paper
